Since 2020, federal and state regulations regarding methadone treatment have been transformed, opening up new avenues of care through Medicare reimbursements for people with opioid use disorders to access medication-assisted treatment (MAT). As opioid settlement funds flood counties nationwide, the continuous fine-tuning of regulations regarding MAT and Opioid Treatment Programs (OTPs) should be a nationwide policy focus.

Just last week, the federal government updated methadone treatment options for the first time in 20 years, allowing certain stable patients to bring home their doses rather than visiting a clinic every single day. This change was first enacted during the pandemic for patient safety; four years later, the federal government has joined many states, including Pennsylvania, in making the change permanent.

This removes a serious hurdle for those in long-term treatment, who face a mandatory, daily in-person office visit that significantly restricts their ability to hold a job, make a move or juggle childcare — especially in rural areas, where the nearest methadone clinic can be many miles away. While some providers initially worried that take-home methadone doses would result in abuse of the medication, which subtly replaces some of the effects of synthetic opioids like heroin and staves off withdrawal, studies surveying OTPs who enacted the change found the majority recorded positive results and wanted to keep the system in place.

Another concern was diverted methadone — or methadone prescribed for patients being sold to others. However, studies show that most diverted methadone is originally prescribed for pain, not opioid abuse recovery.

Advertise with us

However, policy updates themselves do not inevitably lead to meaningful change: That would mean freeing methadone from gatekeepers like OTPs, which are currently the only method patients have to access the medication. The majority of those with opioid use disorder (OUD) still don’t have access to any MAT treatment options, which supplement medication with behavioral and mental health support and represent the gold standard for treating opioid addiction.

There’s also little incentive for OTPs to enact these new take-home procedures. Currently, Medicare reimburses OTPs through weekly payment bundles, which generally cover medication administration and in-person counseling. Reimbursements for patients just taking home medications are low — meaning that in order to get more robust compensation, OTPs may cling to in-person medication administration and counseling.

The federal government’s move to free stable methadone patients from daily, in-person medication requirements is a step in the right direction. But truly making MAT available to all the patients requires freeing methadone from its reliance on OTPs.

These outdated recovery models should no longer serve as the gatekeepers to medications that a majority of those with OUD still can’t access. Stable patients in long-term recovery deserve the freedom of take-home methadone, and OTPs must stop standing in the way.